Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GlobeImmune, Inc. (GBIM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00060.0000 (0.00%)
At close: 03:46PM EDT
Advertisement
Sign in to post a message.
  • Z
    Zaida
    HELP. My local bank says there is an ON MARKET bid for GBIM !!!!! I can't find any INFO ???? anybody
  • Y
    Yim
    Would like to start a position but all my accounts dont trade this stock! Etrade does but the fees are high. Any idea which brokerage trades this with no fees?
  • J
    Joe
    Additional info / links to the $NK COVID-19 vaccine effort found in the NK S-4.

    Page 230 of S4 Section - 'Introduction to Our Second-Generation Adenovirus-based Vaccine Technology'

    " By generating an anti-TAA or neoepitope-specific memory T cell population, the potential for prolonged survival can be established."

    Page F-42 of S4 | Section 16. Subsequent Events

    "commercialize products with GlobeImmune’s COVID-19 vaccine program, other Tarmogen-based programs and neoepitopes program in exchange for consideration that license fees within the first two years of the agreement totaling up to $345.0 million in milestone payments related to the successful completion of clinical and regulatory milestones and up to $240.0 million in total milestone payments based on licensed product net sales milestones, and a royalty on net sales of licensed products, on a product-by-product basis ranging..."

    NK S-4 Link = http://archive.fast-edgar.com/20210119/AK2VG22CZC2RMTZ2222R2ZYKSBIDZZ22D232/

    GBIM Tarmogen Platform - https://www.globeimmune.com/platform/technology/
    Bullish
  • T
    Travis
    Joe has done a superb job of piecing everything together regarding this company and its connection to NK/Immunity Bio. Anyone interested in the potential for GBIM needs to read Joe's due diligence report. It is thorough, well researched, and hits the nail on the head. Thank you, Joe!
  • T
    Travis
    Just hold and put your shares up to sell at 20 if you are not prone to panic selling or do not immediately need the money. Do your dd and get comfortable. Dr Soon Shiong is achieving complete remissions in stage 3 cancers and targeting the covid variants with a vaccine and both depend on GBIM licensed products.
  • c
    charles
    I believe news should be coming out soon. Holding till merger.
  • t
    the Found ation
    call Sarah Singleton 415-290-8045 shes our investor relations REP. now that gbim is a majority owned and subsidary of IBRX. I think she has to inform us about the SEPTEMBER filing deadline along with IBRX plan that affects GBIM as shareholders. Let me know what she says. I have a call into her also. The more shareholders call her she will know we're serious.
  • G
    Goran
    So with all the milestone payments coming GBIM's way, and we get paid for manufacturing plus our patents value. I seriously think 1 share of GBIM is worth more than 1 share of NK, because we have such a low float.
    This obvious value will come to light when Patrick Soon-Shiong opens up the curtain of darkness.
    I wish more people knew about this company, as it is a gem.
    Bullish
  • J
    Joe
    From IBRX's recently released 8K, Exhibit: 99.2 :

    "Yeast Program:

    ImmunityBio’s yeast vaccine platform, licensed from our subsidiary GlobeImmune Inc., has been administered to over 800 patients with cancer or infectious diseases in FDA-regulated clinical trials with no SAEs. This platform technology consists of a heat-killed, recombinant S. cerevisiae yeast-based vaccine engineered to express immunogens such as tumor-associated antigens (TAA), pathogen antigens, and tumor-specific neoepitopes. Immunization with this platform elicits CD4+ and CD8+ T-cell responses capable of eliminating tumor cells or pathogen-infected cells."
    Bullish
  • J
    Joe
    $IBRX posted 2 new jobs for GBIM's facility located in Louisville, Colorado last week, 1 new job 2 weeks ago and has 9 open positions total for GBIM alone. Still accumulating!

    https://nant.wd5.myworkdayjobs.com/ImmunityBio/0/refreshFacet/318c8bb6f553100021d223d9780d30be
    Bullish
  • N
    Nivek23
    Where can you buy GBIM? Fidelity does not trade this.

    Tried to get in when it was < $0.10 on a flyer. Hold NK since $2 and CYTR under $1. Figured GBIM could start flying at some point, depending on the latest wave of optimism coming out of NantWorld
  • T
    Travis
    This seems like a really smart way to play the Immunity Bio and NK merger. These guys have 200,000 shares of Immunity Bio so they have a lot more than that of NK post merger. If they just distributed out the shares to GBMI shareholders, it would put this at 3 or 4 times the market cap right now. But wait!----- there's more. It looks like the whole Immunity Bio and NK vaccine protocol is built on licensed products from GBIM. Which means big royalty payments. So the story just keeps getting better and better. One would almost conclude that Patrick Soon Shiong would not let this run up very far before concluding a full buyout. Perhaps if it gets to between 10 and 20 dollars a share, that would tip his hand. The only downside to this stock is some thoughtless paper handed folks who don't understand the intrinsic value and are willing to sell for less.
  • J
    Joe
    I've added a few updates to the original DD report I released on 2/16/21. Since then, additional bullish events have been revealed about the relationship between
    GBIM & $IBRX thanks to IB merging with NK. A few are listed below, but check out the Google Doc for more info.

    - Up to $1 billion + in possible royalty payments from IBRX
    - Dosed 800+ patients with no serious adverse effects with their yeast
    vaccine platform licensed to IBRX, and also recognized by IBRX as a
    subsidiary in numerous filings.
    - 53 total patents, 5 issued in 2020.
    - 8 open job positions at their Louisville, CO. HQ listed on IBRX's
    employment website.
    - Inclusion of GBIM's IBRX shares to the IBRX treasury
    - Departure of former CFO, with no open position listed to replace him in what would be a redundant role in IBRX.

    https://docs.google.com/document/d/1WYQ8D2eHDjkSi09stonYDLODuoancbtL7IigWgUc8XU/

    $CYTR
    GlobeImmune Inc. Due Diligence Report High Level Overview 2 Brief Company Background 3 NantCell (ImmunityBio) Purchase 3 January 2020 GBIM & IB Licensing Agreement 4 Current GBIM Pipeline 5 Intellectual Property 8 Open Job Positions 9 Key Personnel
    GlobeImmune Inc. Due Diligence Report High Level Overview 2 Brief Company Background 3 NantCell (ImmunityBio) Purchase 3 January 2020 GBIM & IB Licensing Agreement 4 Current GBIM Pipeline 5 Intellectual Property 8 Open Job Positions 9 Key Personnel
    docs.google.com
  • t
    the Found ation
    Quilt 3.039 completion of study of the data is shown as april 2021 GI 4100 in use GBIM could have great news any minute
  • c
    charles
    Joe. Thanks for all that info. Any thoughts on the value of GBIM ?
  • F
    Francis C
    well its working... if you believe nantkwest data
  • D
    DotKnight
    Next target 3? 🥁🥁🥁
    Bullish
  • c
    charles
    Sell at the ask. It only has 6 million float.don’t sell market order.
  • c
    charles
    Congrats whoever got the $1.80s. We know it’s not Tony.
  • J
    Joe
    QUICK FACTS.

    - 5 current job postings at their Louisville, CO HQ posted on ImmunityBio's website...

    - 4 platforms under license by ImmunityBio with up to $1 billion in payments. (GI-4000, GI-6100, GI6207, GI-6301)

    - 9 separate QUILT trials, 2 drugs are the sole candidate in the trial

    - essential to the COVID vaccine efforts (check my post on the S-4)

    - 53 patents, 5 issued in 2020 with the latest issued on 12/29/2020 for "Combination immunotherapy compositions against cancer and methods"

    - the author of those patents, Tom King has been with GBIM since 2005 and is now Director of R&D at ImmunityBio

    -200k shares of ImmunityBio
    Bullish
Advertisement
Advertisement